These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23460040)

  • 61. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G; Lindsay S; Bowsher WG
    Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer.
    Merseburger AS; Roesch MC
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):703-715. PubMed ID: 35612551
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
    Pedraza R; Kwart AM
    Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
    Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
    Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.
    Fowler JE; Flanagan M; Gleason DM; Klimberg IW; Gottesman JE; Sharifi R
    Urology; 2000 May; 55(5):639-42. PubMed ID: 10792069
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.
    Yri OE; Bjoro T; Fossa SD
    Eur Urol; 2006 Jan; 49(1):54-8; discussion 58. PubMed ID: 16314038
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
    Crawford ED; Twardowski PW; Concepcion RS; Hafron JM; Harris RG; Moul JW; Gordan LN; Petrylak DP; Atkinson SN; Boldt-Houle DM; Keane TE; Higano CS; Henderson RJ; Kader AK; Hussain MH; Shore ND
    J Urol; 2020 Apr; 203(4):743-750. PubMed ID: 31580749
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.
    Hammerer PG; Wirth MP;
    Urol Int; 2018; 100(1):72-78. PubMed ID: 29183006
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
    Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
    BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
    Chang JI; Bucci J
    J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
    Marks LS
    Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results.
    Jocham D
    Urol Int; 1998; 60 Suppl 2():18-24; discussion 35. PubMed ID: 9607554
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
    Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
    Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Are all LH-RH analogues equally effective in prostate cancer?].
    Fosså SD
    Tidsskr Nor Laegeforen; 2005 Sep; 125(18):2493-5. PubMed ID: 16186869
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
    Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.
    Sarosdy MF; Schellhammer PF; Soloway MS; Vogelzang NJ; Crawford ED; Presti J; Chodak GW; Mitchell P; Porter L
    BJU Int; 1999 May; 83(7):801-6. PubMed ID: 10368200
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
    Iannazzo S; Pradelli L; Carsi M; Perachino M
    Value Health; 2011 Jan; 14(1):80-9. PubMed ID: 21211489
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer.
    Wilke D; Patil N; Hollenhorst H; Bowes D; Rutledge R; Ago C
    Pharmacotherapy; 2018 Mar; 38(3):327-333. PubMed ID: 29337395
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA.
    Masson-Lecomte A; Guy L; Pedron P; Bruyere F; Rouprêt M; Nsabimbona B; Dahan M; Hoffman P; Salomon L; Vordos D; Hoznek A; Le Corvoisier P; Morel P; Abbou C; de la Taille A
    World J Urol; 2013 Apr; 31(2):339-43. PubMed ID: 22527669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.